PKM and glioblastoma: We then assessed the role of PKM2 in treatment resistance using a more clinically relevant intracranial tumor model generated with the human GBM U87/EGFRvIII cell line, which expresses a truncated, constitutively active EGFR mutant frequently expressed in GBM (Fig. 1d, e; Supplementary information, Fig. S1d, f).